Ann Gail Hayes

Title: Ann Gail Hayes: Innovator in Buprenorphine Formulations

Introduction

Ann Gail Hayes is a notable inventor based in Cambridge, GB. She has made significant contributions to the field of pharmaceutical formulations, particularly in the delivery of buprenorphine. Her innovative work has the potential to enhance pain management therapies.

Latest Patents

Hayes holds a patent for "Buprenorphine formulations for intranasal delivery." This patent describes aqueous formulations suitable for intranasal administration that comprise buprenorphine or a physiologically acceptable salt or ester thereof. The formulations include a pectin with a degree of esterification of less than 50%, chitosan, and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or hydroxypropylmethylcellulose. These formulations can induce rapid and prolonged analgesia when delivered intranasally, achieving therapeutic plasma concentrations of buprenorphine within 30 minutes.

Career Highlights

Throughout her career, Ann Gail Hayes has worked with various companies, including Vernalis Limited and Archimedes Development Limited. Her experience in research and development has allowed her to contribute significantly to advancements in drug delivery systems.

Collaborations

Hayes has collaborated with notable professionals in her field, including Phillip John Birch and Peter James Watts. These collaborations have further enriched her research and development efforts.

Conclusion

Ann Gail Hayes is a pioneering inventor whose work in buprenorphine formulations has the potential to transform pain management. Her contributions to pharmaceutical science are noteworthy and continue to influence the field.